Denaverine
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | intramuscular injection, suppositories |
ATCvet code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 8% (suppositories), 37% (oral solution) |
Metabolism | mainly hepatic, at least 11 metabolites |
Elimination half-life | 34 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H33NO3 |
Molar mass | 383.532 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Denaverine is an antispasmodic drug. It was developed in Germany and patented in 1974. Denaverine hydrochloride is used in veterinary medicine under the trade name Sensiblex as a muscle relaxant for the myometrium of cows and dogs during parturition.[1] Under the trade name Spasmalgan, it has also been used in humans for the treatment of urogenital and gastrointestinal spasms.[2]
Mechanism of action
Denaverine, like papaverine, acts as a phosphodiesterase inhibitor. Additionally, it has anticholinergic effects.[3]
References
- ^ Committee for Veterinary Medicinal Products: Denavering Hydrochloride Summary Report
- ^ Dootz H, Kuhlmann A, Hoffmann K (eds.). Rote Liste (in German) (2005 ed.). Aulendorf: Editio Cantor. 77 023. ISBN 3-87193-306-6.
- ^ Dinnendahl V, Fricke U, eds. (2010). Arzneistoff-Profile (in German). Vol. 4 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.